Close

Warning

You are about to leave ethypharm.com

Regulations vary by country. The information provided on the website you wish to visit may not correspond to that of your country.

Click on CONTINUE if you wish to access the site of one of our subsidiaries.

Continue
Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China

Ethypharm is pleased to announce the acquisition of a suppository form of Mesalazine by its Chinese affiliate, Shanghai Ethypharm Pharmaceuticals Ltd, from the Chinese Company Jiangsu Anbison Pharmaceutical.